Infection Update

What's New

Articles from Penetration 2008
The Role of 750 mg Once-Daily Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases
February 7, 2008 update (Lectures)
Quinolones News

Fluoroquinolones best for patients with risk factors predictive of treatment failure (August 18, 2008)

A rat model of foreign body infection suggests that levoflocacin alone is more effective than a combination with rifampin(August 18, 2008)

Quinolones News Archive Selection

Moxifloxacin (AVELOX) and Serious Side Effects
Bayer has sent out letters warning European doctors about a number of reports of serious liver and skin side effects found in patients taking its fluoroquinolone antibiotic, AVELOX(March 17, 2008)

Canadian Levofloxacin Patent Upheld by Federal Appeal Court (June 18, 2007)

US doctors report a case of Torsade de Pointes associated with moxifloxacin use(March 07, 2007)

FDA Panel Urges Limits on Telithromycin (KETEK)
The FDA advisory panel has concluded that telithromycin (KETEK) should not be sold to patients with sinusitis or bronchitis. It could still be used for mild to moderate pneumonia.(December 18, 2006)

Levofloxacin effective in children with recurrent or persistent acute otitis media(December 04, 2006)

FDA has concerns about expanding use of Gemifloxacin (FACTIVE)
Gemifloxacin (FACTIVE), proposed as a treatment for acute sinus infections, should be studied further due to serious skin reactions associated with its use according to FDA documents released on Sep 12, 2006.(September 19, 2006)

A US trial shows that a shorter course of levofloxacin 750 mg for 5 days is just as effective as the longer standard treatment for patients with community-acquired pneumonia(June 05, 2006)

Gatifloxacin (TEQUIN) taken off the market
The makers of gatifloxacin (TEQUIN) has announced that it would no longer manufacture the drug. Gatifloxacin has been associated with both hypoglycemia and hyperglycemia. (May 08, 2006)

Meeting Calendar: 16 meetings are added and 4 meetings are updated.
April 16, 2007 update (Meeting Calendar)
Penetration 2007
Antimicrobial Susceptibility among Streptococcus pneumoniae: Data from the GLOBAL Study 2005/2006. Mark E. Jones, Nina P. Brown, Deborah C. Draghi, Clyde Thornsberry, Daniel F. Sahm. 2007: 15-22 (Review)
Using Safety Profiles to Differentiate between the Newer Fluoroquinolones. Keith A. Rodvold. 2007: 23-30 (Review)
A DRUG FOR ALL SEASONS: Reviewing the Last 15 Years of Continuous Levofloxacin Use (Special Feature Article)



©1998-2008 BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Disclaimer